Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(157 produtos)
- Bcr-Abl(113 produtos)
- EGFR(596 produtos)
- FAK(72 produtos)
- FLT(88 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(180 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(52 produtos)
- VDA(2 produtos)
- VEGFR(250 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2002 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
VEGFR-2/DHFR-IN-1
Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.Fórmula:C20H18ClNO4Cor e Forma:SolidPeso molecular:371.81FLT3-IN-32
CAS:FLT3-IN-32 is a potent FLT3 inhibitor with high selectivity, effectively suppressing FLT3 activating mutations and inducing apoptosis. It demonstrates good tolerance in non-tumor-bearing mice. In NOD/SCID mice loaded with MV4-11 cells, FLT3-IN-32 exhibits outstanding antitumor efficacy, significantly extending mouse survival. FLT3-IN-32 is applicable for acute myeloid leukemia research.Fórmula:C28H29N5O5Cor e Forma:SolidPeso molecular:515.56(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Fórmula:C25H22N6O2Cor e Forma:SolidPeso molecular:438.48EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Fórmula:C27H25N3O6SCor e Forma:SolidPeso molecular:519.57EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Fórmula:C12H14N4OS2Cor e Forma:SolidPeso molecular:294.4DBMB
CAS:DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.Fórmula:C24H22N4OCor e Forma:SolidPeso molecular:382.458Tuspetinib dihydrochloride
CAS:Tuspetinib (HM43239) dihydrochloride is a selective FLT3 inhibitor with oral bioactivity, exhibiting IC50 values of 1.1 nM for FLT3 wild type, 1.8 nM for FLT3ITD mutant type, and 1.0 nM for FLT3D835Y mutant type. As a reversible type I inhibitor, it directly suppresses FLT3 kinase activity and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib dihydrochloride inhibits the proliferation of leukemia cells and induces apoptosis (apoptosis).Fórmula:C29H35Cl3N6Cor e Forma:SolidPeso molecular:573.99HPK1-IN-61
CAS:HPK1-IN-61 (Compound 1) serves as an inhibitor of hematopoietic progenitor kinase 1 (HPK1) with a Ki of 0.4 nM, and also inhibits Abl with an IC50 of less than 0.51 nM. Additionally, HPK1-IN-61 displays inhibitory activity against LCK, with an IC50 of 24 nM.Fórmula:C23H22N4O2Cor e Forma:SolidPeso molecular:386.45WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Fórmula:C33H45BrN8O5SCor e Forma:SolidPeso molecular:745.73CEP-7055
CAS:CEP-18770: oral proteasome inhibitor; blocks NF-kappaB; may cause cancer cell apoptosis; less toxic than bortezomib in normal cells.Fórmula:C32H35N3O4Cor e Forma:SolidPeso molecular:525.64HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Fórmula:C28H26F3N7O3Cor e Forma:SolidPeso molecular:565.55Ifebemtinib tosylate
CAS:Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor with anti-tumor properties. It inhibits FAK autophosphorylation in prostate cancer cells and suppresses spheroid formation and in situ tumor growth in vivo. Ifebemtinib (tosylate) is applicable in cancer research, including studies on solid tumors, breast cancer, and malignant pleural mesothelioma.Fórmula:C35H36F4N6O7SCor e Forma:SolidPeso molecular:760.76BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Fórmula:C23H22FN5O3Cor e Forma:SolidPeso molecular:435.45CEP-11981
CAS:CEP-11981 is an orally active TIE2/pan-VEGFR inhibitor with broad tyrosine kinase inhibitory activity, antitumour and anti-angiogenic, refractory solid tumours.Fórmula:C28H27N7OPureza:99.58%Cor e Forma:SolidPeso molecular:477.56FGFR-IN-16
CAS:FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.Fórmula:C30H27Cl2N7O4Cor e Forma:SolidPeso molecular:620.49VEGFR-2-IN-38
CAS:VEGFR-2-IN-38 (compound 3) acts as a potential inhibitor of the vascular endothelial growth factor receptor-2 [1].Fórmula:C17H12N4SCor e Forma:SolidPeso molecular:304.37EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Fórmula:C25H24ClN7O2Cor e Forma:SolidPeso molecular:489.96EGFR-IN-44
EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.Fórmula:C27H29ClN6O2SCor e Forma:SolidPeso molecular:537.08VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Fórmula:C24H18N6O2SCor e Forma:SolidPeso molecular:454.5FGFR4-IN-7
FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.Fórmula:C26H25Cl2N5O3Cor e Forma:SolidPeso molecular:526.41
